Close Menu

NEW YORK (GenomeWeb) – Amarantus Bioscience said today that it has reacquired the rights to three neurology diagnostic tests from Avant Diagnostics.

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro. Under the terms of the deal, Amarantus will cancel all liabilities, totaling about $722,000, owed by Avant. Amarantus will issue to Avant 1 million shares of its common stock, and Avant will issue to Amarantus an additional 32 million shares of its common stock as a repayment of debt.

Amarantus said it plans to assign the diagnostic assets to a new subsidiary.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.